Wall Street brokerages expect ContraFect Corporation (NASDAQ:CFRX) to report earnings per share of ($0.11) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for ContraFect Corporation’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.12). ContraFect Corporation posted earnings of ($0.28) per share in the same quarter last year, which would suggest a positive year over year growth rate of 60.7%. The business is expected to report its next earnings results on Wednesday, November 8th.

On average, analysts expect that ContraFect Corporation will report full-year earnings of ($0.43) per share for the current year, with EPS estimates ranging from ($0.46) to ($0.40). For the next financial year, analysts forecast that the company will report earnings of ($0.42) per share, with EPS estimates ranging from ($0.50) to ($0.34). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for ContraFect Corporation.

ContraFect Corporation (NASDAQ:CFRX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.11.

Separately, Maxim Group reiterated a “hold” rating on shares of ContraFect Corporation in a research note on Thursday, May 25th.

In related news, Director Sol J. Barer bought 40,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were bought at an average price of $1.24 per share, with a total value of $49,600.00. Following the transaction, the director now owns 815,933 shares in the company, valued at $1,011,756.92. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders have purchased 50,800 shares of company stock valued at $62,992. 9.30% of the stock is currently owned by company insiders.

A hedge fund recently bought a new stake in ContraFect Corporation stock. Westfield Capital Management Co. LP bought a new stake in shares of ContraFect Corporation (NASDAQ:CFRX) during the first quarter, according to its most recent 13F filing with the SEC. The firm bought 149,600 shares of the biotechnology company’s stock, valued at approximately $269,000. Westfield Capital Management Co. LP owned approximately 0.36% of ContraFect Corporation at the end of the most recent quarter. 25.22% of the stock is owned by institutional investors.

ContraFect Corporation (NASDAQ CFRX) traded down 2.083% during midday trading on Tuesday, hitting $1.175. 102,268 shares of the stock were exchanged. The firm’s 50 day moving average price is $1.31 and its 200 day moving average price is $1.59. ContraFect Corporation has a 12 month low of $1.00 and a 12 month high of $3.28. The company’s market cap is $86.55 million.

TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/20/contrafect-corporation-cfrx-expected-to-announce-earnings-of-0-11-per-share.html.

Get a free copy of the Zacks research report on ContraFect Corporation (CFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ContraFect Corporation (NASDAQ:CFRX)

Receive News & Stock Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related stocks with our FREE daily email newsletter.